2/14/2023 | BK | Supernus closes on $150 million revolving line of credit
|
12/7/2018 | CV | Market Commentary: Tesla’s 0.25% convertibles ‘getting interesting,’ other notes gain; Supernus below par
|
3/20/2018 | CV | Supernus greenshoe lifts five-year convertibles to $402.5 million
|
3/16/2018 | CV | Market Commentary: Zendesk, Live Nation convertibles hit the market, dominate trading; recent deals strong
|
3/16/2018 | CV | Market Commentary: Morning Commentary: Zendesk, Live Nation convertibles hit the market in early trading
|
3/15/2018 | CV | Market Commentary: Supernus convertibles price rich, expand on debut; Zendesk, Live Nation deals on tap
|
3/15/2018 | CV | Market Commentary: Morning Commentary: Supernus prices rich, expands on debut; Zendesk, Live Nation on tap
|
3/15/2018 | CV | New Issue: Supernus prices $350 million five-year convertible notes to yield 0.625%, up 37.5%
|
3/14/2018 | CV | Market Commentary: Zendesk, Supernus on tap; Helix Energy convertibles price cheap, dominate trading
|
3/14/2018 | CV | Market Commentary: Morning Commentary: Helix Energy convertibles price cheap; market awaits Supernus offering
|
3/13/2018 | CV | Market Commentary: Helix, Supernus convertibles on tap; Deutsche Bank eyed; new paper, tech names active
|
3/13/2018 | CV | Supernus Pharmaceuticals talks $350 million five-year convertibles at 0.75%-1.25%, up 32.5%-37.5%
|
2/24/2017 | SP | New Issue: JPMorgan sells $1 million 9% yield notes on Supernus Pharmaceuticals
|
10/24/2013 | CV | Supernus adjusts cap on shares issuable upon conversion of 7.5% notes
|
5/6/2013 | CV | Supernus greenshoe exercised, lifts 7.5% convertibles to $90 million
|
4/26/2013 | CV | New Issue: Supernus prices $75 million six-year convertible notes to yield 7.5%, up 17.5%
|
4/26/2013 | CV | Market Commentary: New Supernus jumps outright, adds on hedge; Theravance contracts on hedge; D.R. Horton up
|
4/25/2013 | CV | Market Commentary: PennyMac adds to 101; planned Supernus eyed; Microsoft adds; Theravance to split company
|
4/24/2013 | CV | Supernus plans $75 million convertible notes due 2019 to yield 7%-7.5%, up 15%-20%
|
4/24/2013 | CV | Market Commentary: Planned PennyMac seen fair value to slightly cheap; Nuance trades in line; Supernus on tap
|
11/30/2012 | PP | Supernus prices $48 million public offering of common stock at $8.00
|
11/14/2012 | PP | Supernus Pharmaceuticals reports plans to price public sale of stock
|
5/1/2012 | PP | Supernus Pharmaceuticals prices its $50 million IPO of common stock
|
6/13/2006 | BT | Supernus, United Therapeutics form partnership to develop UT-15C for hypertension
|
2/21/2006 | BT | Supernus closes second round of series A financing for $17.5 million
|
1/12/2006 | BT | New pharma company Supernus acquires Shire Labs assets, raises $17.5 million in venture capital
|